Csl Behring
KING OF PRUSSIA, Pennsylvania, May 31, 2011 -
CSL Behring announced today that it has been granted Orphan Drug
Designations (ODD) by the European Commission for the development of its
recombinant fusion protein linking coagulation factor VIIa with albumin
(rVIIa-FP), a novel therapy to treat hemophilia A and hemophilia B patients
with inhibitors.
BERN, Switzerland, April 21, 2011 - CSL Behring announced today that the European Commission has granted
marketing authorization for Hizentra(R) (Human Normal Immunoglobulin), 20
percent solution for subcutaneous injection, for treating patients diagnosed
with primary immunodeficiency (PI) as well as secondary immunodeficiencies.
PARIS, February 28, 2011 - CSL Behring announces a special edition of its Key Issues Dialogue series
released in conjunction with Rare Disease Day 2011, an international event to
raise awareness of rare diseases and their impact on people's lives.
LONDON, June 9, 2010 - The HAE Awareness Programme was launched today, an online
interactive training programme aimed to increase awareness of Hereditary
Angioedema (HAE).
EDINBURGH, Scotland, February 4 - CSL Behring announced today the start of the global clinical trial
program SWIFT (Studies with von Willebrand factor [VWF]/Factor VIII) to
evaluate the pharmacokinetics, efficacy and safety of Biostate(R), a
low-volume, highly active, plasma-derived VWF/FVIII concentrate for the
treatment of von Willebrand disease (VWD) and hemophilia A.
